Sotorasib Shows Modest Activity in KRAS G12C Pancreatic Cancer
This trial provides the first prospective efficacy and safety data for a KRAS G12C inhibitor in a rare molecular subset of previously treated pancreatic cancer, informing off-label and future use decisions.
Sotorasib offers hope for KRAS p.G12C-mutated pancreatic cancer.
KRAS p.G12C mutation is present in a small percentage of pancreatic cancers, highlighting the need for targeted treatments like sotorasib. In the trial, 21% of patients had a confirmed objective response to sotorasib, with a median progression-free survival of 4.0 months and overall survival of 6.9 months. Sotorasib demonstrates potential as a targeted therapy for advanced pancreatic cancer with KRAS p.G12C mutation, offering a new option for previously treated patients. Sotorasib shows promise with manageable safety in KRAS p.G12C-mutated advanced pancreatic cancer.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.